Review



human garp  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    R&D Systems human garp
    Human Garp, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+garp/us12006372-495-46-48?v=R%26D+Systems
    Average 92 stars, based on 4 article reviews
    human garp - by Bioz Stars, 2026-07
    92/100 stars

    Images



    Similar Products

    94
    MedChemExpress recombinant human tgf
    Recombinant Human Tgf, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+garp/10__1161_slash_atvbaha__125__324134-199-3-10?v=MedChemExpress
    Average 94 stars, based on 1 article reviews
    recombinant human tgf - by Bioz Stars, 2026-07
    94/100 stars
      Buy from Supplier

    91
    Miltenyi Biotec anti garp pe antibodies
    Anti Garp Pe Antibodies, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+garp/pm37994568-37-12-24?v=Miltenyi+Biotec
    Average 91 stars, based on 1 article reviews
    anti garp pe antibodies - by Bioz Stars, 2026-07
    91/100 stars
      Buy from Supplier

    92
    R&D Systems human garp
    Human Garp, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+garp/us12006372-495-46-48?v=R%26D+Systems
    Average 92 stars, based on 1 article reviews
    human garp - by Bioz Stars, 2026-07
    92/100 stars
      Buy from Supplier

    90
    BioWa Inc humanized anti-human garp antibody h151d-h4l4
    Humanized Anti Human Garp Antibody H151d H4l4, supplied by BioWa Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+garp/us12006372-758-14-29?v=BioWa+Inc
    Average 90 stars, based on 1 article reviews
    humanized anti-human garp antibody h151d-h4l4 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    BioWa Inc humanized anti-human garp antibody h198d-h3l4
    Humanized Anti Human Garp Antibody H198d H3l4, supplied by BioWa Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+garp/us12006372-759-14-29?v=BioWa+Inc
    Average 90 stars, based on 1 article reviews
    humanized anti-human garp antibody h198d-h3l4 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    R&D Systems anti-human garp antibody
    Anti Human Garp Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+garp/us12006372-800-3-13?v=R%26D+Systems
    Average 90 stars, based on 1 article reviews
    anti-human garp antibody - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    91
    OriGene lrrc32 overexpression plasmid
    Figure 1. (A) Flow cytometric analysis of surface <t>GARP</t> and CD133 on different GSCs and the control, non-stem, GB cell line, T98G. Doublets, debris, and dead cells were excluded from the analysis. Mean fluorescence intensity (MFI) was normalized to the MFI of the respective unstained control. (B) Confocal images of GARP- and nestin-expressing GSCs and T98G. Cells were stained for GARP (red) and nestin (green). Cells were counterstained for their nuclei with Hoechst (blue). Note the intranuclear localization of GARP (NU+). Scale bar corresponds to 20 µm. (C) Percentage of GARPNU+ cells were determined by counting GARP stained nuclei. “No.” indicates the number of counted cells for the analysis.
    Lrrc32 Overexpression Plasmid, supplied by OriGene, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+garp/pm38136258-66-30-33?v=OriGene
    Average 91 stars, based on 1 article reviews
    lrrc32 overexpression plasmid - by Bioz Stars, 2026-07
    91/100 stars
      Buy from Supplier

    Image Search Results


    Figure 1. (A) Flow cytometric analysis of surface GARP and CD133 on different GSCs and the control, non-stem, GB cell line, T98G. Doublets, debris, and dead cells were excluded from the analysis. Mean fluorescence intensity (MFI) was normalized to the MFI of the respective unstained control. (B) Confocal images of GARP- and nestin-expressing GSCs and T98G. Cells were stained for GARP (red) and nestin (green). Cells were counterstained for their nuclei with Hoechst (blue). Note the intranuclear localization of GARP (NU+). Scale bar corresponds to 20 µm. (C) Percentage of GARPNU+ cells were determined by counting GARP stained nuclei. “No.” indicates the number of counted cells for the analysis.

    Journal: Cancers

    Article Title: Nuclear Glycoprotein A Repetitions Predominant (GARP) Is a Common Trait of Glioblastoma Stem-like Cells and Correlates with Poor Survival in Glioblastoma Patients.

    doi: 10.3390/cancers15245711

    Figure Lengend Snippet: Figure 1. (A) Flow cytometric analysis of surface GARP and CD133 on different GSCs and the control, non-stem, GB cell line, T98G. Doublets, debris, and dead cells were excluded from the analysis. Mean fluorescence intensity (MFI) was normalized to the MFI of the respective unstained control. (B) Confocal images of GARP- and nestin-expressing GSCs and T98G. Cells were stained for GARP (red) and nestin (green). Cells were counterstained for their nuclei with Hoechst (blue). Note the intranuclear localization of GARP (NU+). Scale bar corresponds to 20 µm. (C) Percentage of GARPNU+ cells were determined by counting GARP stained nuclei. “No.” indicates the number of counted cells for the analysis.

    Article Snippet: Antibody specificity was demonstrated using GARP-overexpressing Mewo cells, resulting from transient transfection using the LOX-IMVI Cell Avalanche Transfection Reagent (EZ Biosystems, EZT-LOXI-1, College Park, MD, USA) as well as a LRRC32 overexpression plasmid (Origene, SC116699) and an empty vector control plasmid (Origene, PS100001) (Figure S3).

    Techniques: Control, Fluorescence, Expressing, Staining

    Figure 2. GARP expression in isogenic GSCs derived from newly diagnosed GB IT-726. Flow cytometric analysis of IT-726-1, -2, -3a, -3b, and -4. Doublets, debris, and dead cells were excluded from analysis. Mean fluorescence intensity (MFI) was normalized to the MFI of the unstained control. Histograms display one representative result of three independent measurements. Data are displayed as mean values ± SEM.

    Journal: Cancers

    Article Title: Nuclear Glycoprotein A Repetitions Predominant (GARP) Is a Common Trait of Glioblastoma Stem-like Cells and Correlates with Poor Survival in Glioblastoma Patients.

    doi: 10.3390/cancers15245711

    Figure Lengend Snippet: Figure 2. GARP expression in isogenic GSCs derived from newly diagnosed GB IT-726. Flow cytometric analysis of IT-726-1, -2, -3a, -3b, and -4. Doublets, debris, and dead cells were excluded from analysis. Mean fluorescence intensity (MFI) was normalized to the MFI of the unstained control. Histograms display one representative result of three independent measurements. Data are displayed as mean values ± SEM.

    Article Snippet: Antibody specificity was demonstrated using GARP-overexpressing Mewo cells, resulting from transient transfection using the LOX-IMVI Cell Avalanche Transfection Reagent (EZ Biosystems, EZT-LOXI-1, College Park, MD, USA) as well as a LRRC32 overexpression plasmid (Origene, SC116699) and an empty vector control plasmid (Origene, PS100001) (Figure S3).

    Techniques: Expressing, Derivative Assay, Fluorescence, Control

    Figure 3. Analysis of expression and localization of GARP in isogenic GSC cell lines, which vary in differentiation states derived from different regions of the same tumor. (A) Number of GARP positive nuclei for GSC lines IT-726—1, -2, -3A, and -4 were analyzed by counting double positive (Hoechst and GARP) cell nuclei (NU+). “No.” indicates the number of counted cells for the analysis. (B) Confocal images of GARP- and nestin-expressing GSC IT-726 -2 and -4. Cells were stained for their nuclei with Hoechst (blue), GARP (red), and nestin (green). Note the intranuclear localization of GARP. Scale bar corresponds to 20 µm.

    Journal: Cancers

    Article Title: Nuclear Glycoprotein A Repetitions Predominant (GARP) Is a Common Trait of Glioblastoma Stem-like Cells and Correlates with Poor Survival in Glioblastoma Patients.

    doi: 10.3390/cancers15245711

    Figure Lengend Snippet: Figure 3. Analysis of expression and localization of GARP in isogenic GSC cell lines, which vary in differentiation states derived from different regions of the same tumor. (A) Number of GARP positive nuclei for GSC lines IT-726—1, -2, -3A, and -4 were analyzed by counting double positive (Hoechst and GARP) cell nuclei (NU+). “No.” indicates the number of counted cells for the analysis. (B) Confocal images of GARP- and nestin-expressing GSC IT-726 -2 and -4. Cells were stained for their nuclei with Hoechst (blue), GARP (red), and nestin (green). Note the intranuclear localization of GARP. Scale bar corresponds to 20 µm.

    Article Snippet: Antibody specificity was demonstrated using GARP-overexpressing Mewo cells, resulting from transient transfection using the LOX-IMVI Cell Avalanche Transfection Reagent (EZ Biosystems, EZT-LOXI-1, College Park, MD, USA) as well as a LRRC32 overexpression plasmid (Origene, SC116699) and an empty vector control plasmid (Origene, PS100001) (Figure S3).

    Techniques: Expressing, Derivative Assay, Staining

    Figure 4. Quantitative assessments of self-renewal capacity by extreme limiting dilution assay (ELDA). (A) Representative results. (B) The pooled results from three independent experiments are indicated in the table. GARPhigh and GARPlow correspond to isogenic GSCs differing in their GARP expression, which were FACs sorted from the GSC line #1095. Estimates of the stem cell frequency (SCF) are framed in red, while lower and upper indicate the confidence intervals for 1/SCF. Statistical significance between groups was calculated by chi-squared tests.

    Journal: Cancers

    Article Title: Nuclear Glycoprotein A Repetitions Predominant (GARP) Is a Common Trait of Glioblastoma Stem-like Cells and Correlates with Poor Survival in Glioblastoma Patients.

    doi: 10.3390/cancers15245711

    Figure Lengend Snippet: Figure 4. Quantitative assessments of self-renewal capacity by extreme limiting dilution assay (ELDA). (A) Representative results. (B) The pooled results from three independent experiments are indicated in the table. GARPhigh and GARPlow correspond to isogenic GSCs differing in their GARP expression, which were FACs sorted from the GSC line #1095. Estimates of the stem cell frequency (SCF) are framed in red, while lower and upper indicate the confidence intervals for 1/SCF. Statistical significance between groups was calculated by chi-squared tests.

    Article Snippet: Antibody specificity was demonstrated using GARP-overexpressing Mewo cells, resulting from transient transfection using the LOX-IMVI Cell Avalanche Transfection Reagent (EZ Biosystems, EZT-LOXI-1, College Park, MD, USA) as well as a LRRC32 overexpression plasmid (Origene, SC116699) and an empty vector control plasmid (Origene, PS100001) (Figure S3).

    Techniques: Limiting Dilution Assay, Expressing

    Figure 6. GARP expression in GB is unaffected throughout therapy. (A) Survival analysis of GARP and CD133 based on data available through The Cancer Genome Atlas (TCGA). GARP and CD133 mRNA expression data of 152 primary glioblastomas were divided 50/50 into either “low” expres- sion or “high” expression and were analyzed for patient survival. (B) Retrospective analysis of transcriptomic data of 155 GB samples from 28 patients of Kim et al., 2020 [32]. ndGBs, first, and second recurrent tumors were analyzed for their GARP and CD133 mRNA levels across tumor stages. (C) Flow cytometric analysis of IT-619 and IT-654. Doublets, debris, and dead cells were excluded from analysis. Recurrent IT-654 GSCs exhibited stable surface GARP levels after TMZ and radiotherapy, whereas expression of CD133 decreased after treatment. The MFIs were normalized to the unstained control. n = 3. Significance was calculated by Student´s t-test and is indicated as follows: * p < 0.05, *** p < 0.001, and ns (not significant). (D) Number of GARP-positive nuclei for GSC IT-619 and IT-654 were analyzed by counting double-positive (Hoechst and GARP) cell nuclei. “No.” indicates the number of counted cells for the analysis.

    Journal: Cancers

    Article Title: Nuclear Glycoprotein A Repetitions Predominant (GARP) Is a Common Trait of Glioblastoma Stem-like Cells and Correlates with Poor Survival in Glioblastoma Patients.

    doi: 10.3390/cancers15245711

    Figure Lengend Snippet: Figure 6. GARP expression in GB is unaffected throughout therapy. (A) Survival analysis of GARP and CD133 based on data available through The Cancer Genome Atlas (TCGA). GARP and CD133 mRNA expression data of 152 primary glioblastomas were divided 50/50 into either “low” expres- sion or “high” expression and were analyzed for patient survival. (B) Retrospective analysis of transcriptomic data of 155 GB samples from 28 patients of Kim et al., 2020 [32]. ndGBs, first, and second recurrent tumors were analyzed for their GARP and CD133 mRNA levels across tumor stages. (C) Flow cytometric analysis of IT-619 and IT-654. Doublets, debris, and dead cells were excluded from analysis. Recurrent IT-654 GSCs exhibited stable surface GARP levels after TMZ and radiotherapy, whereas expression of CD133 decreased after treatment. The MFIs were normalized to the unstained control. n = 3. Significance was calculated by Student´s t-test and is indicated as follows: * p < 0.05, *** p < 0.001, and ns (not significant). (D) Number of GARP-positive nuclei for GSC IT-619 and IT-654 were analyzed by counting double-positive (Hoechst and GARP) cell nuclei. “No.” indicates the number of counted cells for the analysis.

    Article Snippet: Antibody specificity was demonstrated using GARP-overexpressing Mewo cells, resulting from transient transfection using the LOX-IMVI Cell Avalanche Transfection Reagent (EZ Biosystems, EZT-LOXI-1, College Park, MD, USA) as well as a LRRC32 overexpression plasmid (Origene, SC116699) and an empty vector control plasmid (Origene, PS100001) (Figure S3).

    Techniques: Expressing, Control

    Figure 7. Nuclear GARP is a potential new prognostic biomarker for GB patient survival. (A) Im- munohistochemistry of GARP in glioblastoma. GB (WHO grade IV) with low frequency of labeled

    Journal: Cancers

    Article Title: Nuclear Glycoprotein A Repetitions Predominant (GARP) Is a Common Trait of Glioblastoma Stem-like Cells and Correlates with Poor Survival in Glioblastoma Patients.

    doi: 10.3390/cancers15245711

    Figure Lengend Snippet: Figure 7. Nuclear GARP is a potential new prognostic biomarker for GB patient survival. (A) Im- munohistochemistry of GARP in glioblastoma. GB (WHO grade IV) with low frequency of labeled

    Article Snippet: Antibody specificity was demonstrated using GARP-overexpressing Mewo cells, resulting from transient transfection using the LOX-IMVI Cell Avalanche Transfection Reagent (EZ Biosystems, EZT-LOXI-1, College Park, MD, USA) as well as a LRRC32 overexpression plasmid (Origene, SC116699) and an empty vector control plasmid (Origene, PS100001) (Figure S3).

    Techniques: Biomarker Discovery, Labeling